ClinicalTrials.gg

TargetBeta

EGFR

epidermal growth factor receptor · also ERBB1, ERRP, ERBB · Erb-b2 receptor tyrosine kinases

59 programs in company-led studies act on EGFR, from 46 companies: 24 in phase 3, 2 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (46 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
osimertinibruleAstraZenecaphase 44215 running–NCIt
PanitumumabruleAmgenphase 4433 running–NCIt
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 35555 runningERBB3a judged reading
Anti-EGFR Antibody-drug Conjugate CPO301CSPC Pharmaceutical Groupphase 31616 running–a judged reading
CetuximabruleEli Lillyphase 39013 running–NCIt
amivantamabruleJohnson & Johnsonphase 31613 runningMETNCIt
aflutinibruleAllist Pharmaceuticalsphase 32111 running–NCIt
andamertinibruleAvistone Biotechnologyphase 3109 running–NCIt
pimurutamabFosun Pharmaphase 3178 running–a judged reading
aumolertinibruleHansoh Pharmaceutical Groupphase 3158 running–NCIt
becotatugCSPC Pharmaceutical Groupphase 3118 running–a judged reading
HS-10504Hansoh Pharmaceutical Groupphase 377 running–the company's pipeline
lazertinibruleJohnson & Johnsonphase 3186 running–NCIt
sunvozertinibruleDizal Pharmaceuticalsphase 3125 runningERBB2NCIt
becotatug vedotinruleLepu Biopharmaphase 3105 running–NCIt
petosemtamabruleGenmabphase 365 runningLGR5NCIt
bafisontamabruleShanghai EpimAb Biotherapeuticsphase 354 runningMETNCIt
zipalertinibruleOtsukaphase 344 running–NCIt
ficerafusp alfaruleBicara Therapeuticsphase 333 runningTGFB1NCIt
HS-20117Hansoh Pharmaceutical Groupphase 333 runningMETthe company's pipeline
sevabertinibruleBayerphase 382 runningERBB2NCIt
befotertinibruleBetta Pharmaceuticalsphase 362 running–NCIt
ASK-120067ruleBeijing Aosaikang Pharmaceuticalphase 352 running–the studies' text
zorifertinibruleAlpha Biopharma (Jiangsu)phase 341 running–NCIt
Anti-EGFR/Anti-B7-H3 Bispecific Antibody-drug Conjugate TJ101ruleTJ Biopharmaphase 331 runningCD276NCIt
FHND-9041Sino Biopharmaceuticalphase 311 running–the company's pipeline
TQB2922Sino Biopharmaceuticalphase 255 runningMETthe company's pipeline
silevertinibruleRyvu Therapeuticsphase 274 running–NCIt
pamvatamigruleBetta Pharmaceuticalsphase 254 runningMETNCIt
EGFR Mutant-specific Inhibitor DZD6008ruleDizal Pharmaceuticalsphase 233 running–NCIt
TQB6411Sino Biopharmaceuticalphase 233 runningMETthe company's pipeline
enozertinibruleORIC Pharmaceuticalsphase 232 runningERBB2NCIt
BEBT-109ruleBeBetter Medphase 222 running–the studies' text
EGFR/EGFRvIII Inhibitor WSD0922-FUruleWayshine Biopharmphase 222 running–NCIt
Staphylococcus epidermidis Strain Topical Ointment ATR04-484ruleAzitraphase 221 running–NCIt
VRN110755ruleVoronoiphase 221 running–the studies' text
Anti-EGFR Antibody-PI3K/PIKK Inhibitor Conjugate HMPL-A580ruleHUTCHMEDphase 211 running–NCIt
Anti-EGFR/Anti-c-Met Bispecific Antibody-drug Conjugate VBC101ruleVelaVigo Caymanphase 211 runningMETNCIt
Anti-EGFR/Anti-CDCP1-MMAE Antibody-Drug Conjugate IDP-001ruleInduProphase 211 runningCDCP1NCIt
Anti-EGFR/Anti-HER3 Bispecific Antibody-drug Conjugate AVZO-1418ruleAvenzo Therapeuticsphase 211 runningERBB3NCIt
EGFR/HER2 Mutant-selective Inhibitor BH-30643ruleBlossomHill Therapeuticsphase 211 runningERBB2NCIt
KY-0301ruleNovatim Immune Therapeutics (Zhejiang)phase 211 running–the studies' text
VBC117ruleVelaVigo Caymanphase 211 running–the studies' text
YH32364ruleYuhanphase 211 running–the studies' text
Anti-c-Met/EGFR/VEGF Trispecific Antibody TAVO412ruleTavotek Biotherapeuticsphase 122 runningMET, VEGFANCIt
HS-20122Hansoh Pharmaceutical Groupphase 122 runningMETthe company's pipeline
Anti-EGFR Bispecific Antibody EPI-326ruleEpiBiologicsphase 111 running–NCIt
Anti-EGFR/Anti-MUC1 Bispecific Antibody-drug Conjugate NEOK002ruleNEOK Biophase 111 runningMUC1NCIt
Anti-EGFR/c-Met-CPT-113 Antibody-drug Conjugate JNJ-95437446Johnson & Johnsonphase 111 runningMETa judged reading
Anti-EGFR/c-Met/c-Met-Topoisomerase-1 Inhibitor Trispecific Antibody-drug Conjugate BG-C0902ruleBeOne Medicinesphase 111 runningMETNCIt
Anti-EGFR/CD3 Protease-activated T-cell Engager VIR-5525ruleVir Biotechnologyphase 111 running–NCIt
Anti-EGFR/Top1i ADC ALX2004ruleALX Oncologyphase 111 running–NCIt
CS5007ruleCStone Pharmaceuticalsphase 111 runningERBB3the studies' text
GENSCI139ruleChangchun GeneScience Pharmaceuticalphase 111 runningERBB2the studies' text
HLX48Fosun Pharmaphase 111 runningMETthe company's pipeline
KGX105ruleKangabio AUSTRALIA LTD PTYphase 111 runningCD3Ethe studies' text
MTX-531ruleMEKanistic Therapeuticsphase 111 running–the studies' text
TQB3002Sino Biopharmaceuticalphase 111 running–the company's pipeline
Autologous IL-2-expressing Anti-mesothelin CAR T-cells OPB-101ruleOutpace Biophase 110 runningIL2, MSLNNCIt

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.